<DOC>
	<DOCNO>NCT01478230</DOCNO>
	<brief_summary>Subjects screen within 28 day first study treatment confirm meet requirement participate trial . They return site two treatment visit , least 12 hour , least one day visit . At visit treatment N1/3-I5 Nicotine Inhaler 10 mg administer every hour 11 hour . The investigator ( appropriate delegate investigator site ) obtain informed consent subject . Blood sample draw special schedule . The total predict amount blood sample subject 174 mL whole study . Subjects require follow specific smoke dietary restriction rate urge smoke , general like product , easy product use .</brief_summary>
	<brief_title>An Exploratory Study Comparing Two Nicotine Inhalers</brief_title>
	<detailed_description>Blood pharmacokinetic analysis draw prior first administration immediately administration 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 hour . Thereafter sample drawn 5 , 10 , 15 , 20 , 25 , 30 , 45 , 60 minute 11-hour administration . Easiness use rat use 8-grade ordered category scale 10 minute start administration 3 , 6 , 9 hour . Overall liking rat use 8-grade ordered category scale 12 hour . Urges smoke rat 4-grade ordered category scale immediately 15 minute first administration , well 15 minute start administration 3 , 6 , 9 hour , 12 hour . Used cartridge collect . Pooled sample per subject treatment analyze determine amount remain nicotine . Tolerability treatment evaluate term report observed adverse event ( AE ) . Since primary objective compare steady-state nicotine pharmacokinetics N1/3-I5 Nicotine Inhaler 10 mg , study multiple-dose setting . A crossover design choose study order allow within-subject comparison treatment . Healthy habituate adult smoke least 10 cigarette daily least one year precede inclusion include study , since expect tolerate dos nicotine administer .</detailed_description>
	<mesh_term>Tobacco Use Disorder</mesh_term>
	<mesh_term>Nicotine</mesh_term>
	<criteria>Healthy ( per protocolspecified parameter ) male female subject age 19 50 year , inclusive . Smoking least 10 cigarette daily least one year precede inclusion . For female : Postmenopausal state premenopausal/perimenopausal state protocolspecified effective mean contraception declare absence sexual contact male partner study . For male : No pregnant spouse partner screen willingness protect potential spouse partner become pregnant study . Body Mass Index ( BMI ) within protocolspecified parameter . A personally sign date informed consent document indicate subject inform pertinent aspect study . Willingness ability comply schedule visit , treatment plan , laboratory test , study procedure specify protocol Evidence history acute chronic medical psychiatric condition allergy laboratory abnormality , use drug , judgment investigator authorize study physician , may increase risk associate study participation interfere interpretability study result . Females : Pregnancy , breastfeeding , premenopausal , perimenopausal , state insufficient contraception specify Inclusion Criteria . Males : Pregnant spouse partner willingness prevent conception spouse partner . History regular alcohol consumption outside protocolspecified allowance . Treatment investigational drug within 3 month precede first dose study treatment . Known sensitivity heparin history heparininduced thrombocytopenia . Pathological oral status interfere normal muscular , sensory , absorptive function oral cavity . Piercing tongue lip consider impair oral function . Relationship person involve directly conduct study , family .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Pharmacokinetics</keyword>
</DOC>